Adjuvant Capital, AXA IM and Novo led a $37m Series A round in LimmaTech Biologics.

Adjuvant Capital, a life sciences investment fund, AXA IM, a global investment management firm, and Novo, a life science investor, led a $37m Series A round in LimmaTech Biologics, a clinical stage biopharmaceutical company. “We are thrilled to support LimmaTech’s pipeline of much needed vaccine candidates, with the potential to significantly improve health outcomes globally. The investment reflects Novo Holdings’ continued commitment to tackling antimicrobial resistance, and we believe that with its outstanding record of success in the vaccine field, its seasoned leadership and its promising technology, LimmaTech represents a very attractive investment opportunity, which we are pleased to pursue in partnership with leading investors,” Camilla Petrycer, Novo Principal.